You can also read the IBTA e-News January 2020 edition in full online here.
Some of the highlights from this month's round-up:
- Novocure, developer of the Tumor Treating Fields device Optune, has announced that the Ministry of Health in Israel has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients with newly diagnosed glioblastoma.
- In the journal Scientific Reports, a research team from the University of Birmingham, UK, has shown how it may be possible to measure chemical biomarkers of prognosis in paediatric brain tumours with MRI scanning alone to determine levels of aggressiveness in a tumour. In this widely reported study, the chemical signatures of the amino acid glutamine and lipid (fat) concentrations were reliably calculated with MRI investigations.
- The National Brain Tumor Society (US) will provide USD $200,000 in funding to support an upcoming Phase II trial in a subset of high grade gliomas of ONC201 – a dopamine receptor D2 antagonist (DRD2) .The clinical trial will evaluate the efficacy of single agent ONC201 in patients who have a recurrent form of high-grade glioma that exhibits low expression of epidermal growth factor receptor (EGFR), which is associated with elevated DRD2 expression and ONC201 sensitivity.
- A study has shown that TAU protein, a molecule classically associated with neurodegenerative disorders such as Alzheimer's disease, is linked to better prognosis in patients with glioma.
- Results of a two-part, phase I/IIa, open-label study of the drug dabrafenib (Tafinlar) have shown anti-tumour activity in paediatric patients with recurrent or refractory BRAF V600 mutation, according to the findings. These results have been published in Clinical Cancer Research.
- Researchers have discovered a novel technique to potentially enhance brain tumour immunotherapy, which capitalises on the network of ‘drainage’ channels from the brain – known as the lymphatic system. By introducing a protein that stimulates lymphatic drainage (vascular endothelial growth factor C or “VEGF-C”) into the spinal fluid of animals with glioblastoma being treated with checkpoint inhibitor immunotherapy, the body’s immune cells could better access and attack the brain tumour, leading to better survival than those animals not receiving VEGF-C.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.